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Abstract
The therapeutic potential of plumbagin, a naphthoquinone extracted from the ofﬁcinal
leadwort with anticancer properties, is hampered by its failure to speciﬁcally reach tu-
mours at a therapeutic concentration after intravenous administration, without secondary
effects on normal tissues. Its use in clinic is further limited by its poor aqueous solubility,
its spontaneous sublimation, and its rapid elimination in vivo. We hypothesize that the en-
trapment of plumbagin within liposomes grafted with transferrin, whose receptors are
overexpressed on many cancer cells, could result in a selective delivery to tumours after
intravenous administration. The objectives of this study were therefore to prepare and
characterize transferrin-targeted liposomes entrapping plumbagin and to evaluate their
therapeutic efﬁcacy in vitro and in vivo. The entrapment of plumbagin in transferrin-
bearing liposomes led to an increase in plumbagin uptake by cancer cells and improved an-
tiproliferative efﬁcacy and apoptosis activity in B16-F10, A431, and T98G cell lines com-
pared with that observed with the drug solution. In vivo, the intravenous injection of
transferrin-bearing liposomes entrapping plumbagin led to tumour suppression for 10% of
B16-F10 tumours and tumour regression for a further 10% of the tumours. By contrast,
all the tumours treated with plumbagin solution or left untreated were progressive. The
animals did not show any signs of toxicity. Transferrin-bearing liposomes entrapping
plumbagin are therefore highly promising therapeutic systems that should be further opti-
mized as a therapeutic tool for cancer treatment.
Introduction
Cancer, the second leading cause of death in the world,
accounted for 9.6 million deaths in 2018 and continues
rising worldwide, with an estimation of 16.4 million
deaths in 2040 (Bray et al., 2018). Although several
therapeutic strategies, such as surgery, radiotherapy,
and immunotherapy, can be efﬁcacious against cancers,
chemotherapy remains an important treatment for pa-
tients diagnosed with cancer (Palumbo et al., 2013).
Among the current anticancer drugs approved from
the late 1930s to 2014, approximately 55% were derived
from natural sources (Newman & Cragg, 2016). For
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example, paclitaxel (from the Paciﬁc yew tree), doxo-
rubicin (from Streptomyces peucetius bacterium), vin-
cristine (from the periwinkle plant), topotecan (from
the Camptotheca acuminate tree), and etoposide (from
the mayapple plant Podophyllum peltatum) are well-
established drugs available in the market for cancer
treatment. In addition, several natural-derived com-
pounds, such as isoﬂavones (from soy bean), curcumin
oils (from turmeric), and resveratrol (from grape seed)
are currently being investigated in clinical trials (Cragg
& Pezzuto, 2016). Natural products are therefore an im-
portant channel for the discovery of new anticancer
agents.
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoqui-
none), a natural-derived naphthoquinone, isolated
from the roots of Plumbaginaceae plants (Checker
et al., 2018), has been reported to have anticancer ef-
fect in various types of cancer, including breast, lung,
prostate, cervical, liver, colon, brain, and melanoma
cancers (Panichayupakaranant & Ahmad, 2016;
Rajalakshmi et al., 2018; Checker et al., 2018). These
anticancer effects are mediated through the modula-
tion of cellular redox balance and reduction of glutathi-
one levels, as well as through the activation of
apoptotic pathways in cancer cells (Checker et al.,
2018). Numerous studies have demonstrated that
plumbagin targets several signalling pathways, such as
p53, p38, MAPK, STAT3, NF-κB, FOXM1, MMP2/9,
VEGFR2, Ras, Sirtuin1, caspase-3, JNK, and Wnt/β-
catenin (Sandur et al., 2006; Seshadri et al., 2011; Lai
et al., 2012; Niu et al., 2015; Pan et al., 2015; Wang
et al., 2015; Zhou et al., 2015; Xue et al., 2016).
Plumbagin therefore can be considered as a highly
promising agent for cancer therapy, due to its wide
spectrum anticancer effects.
However, plumbagin has some limitations that signif-
icantly hampered its clinical translation, such as poor
solubility in water (79 μg/mL) (Pawar et al., 2016), high
lipophilicity (log P 3.04) (Pawar et al., 2016), lack of
stability (spontaneous sublimation), and low oral bio-
availability (less than 40%) (Hsieh et al., 2006). Further-
more, this compound is unable to reach tumours at a
therapeutic concentration due to its lack of tumour
speciﬁcity and rapid elimination (biological half-life of
only 35.89 ± 7.95 min) (Kumar et al., 2011).
To overcome this limitation, we hypothesize that
loading plumbagin within liposomes that have the abil-
ity to entrap this lipophilic drug would improve its wa-
ter solubility, prolong its blood circulation time, and
sustain its release over a period of time would improve
the efﬁcacy of the treatment while reducing the ad-
verse effects of the drug. Several thermosensitive and
PEGylated liposomes have been developed to overcome
the drawback of plumbagin but with limited efﬁcacy so
far (Tiwari et al., 2002; Kumar et al., 2011). They
displayed a limited drug loading, were prone to drug
leakage, and were unstable. In addition,
thermosensitive liposomes could not be translatable
to clinical use.
In this study, we developed a new formulation of
plumbagin-loaded liposomes, composed of hydroge-
nated phosphatidylcholine, cholesterol, distearoyl-sn-
glycero-3-phosphoethanolamine, with a mixture of
low and high molecular weight PEG (2000 and
5000 Da) at high concentrations to obtain sterically sta-
bilized liposomes. These liposomes will be conjugated
to transferrin (Tf), whose receptors are overexpressed
on many cancer cells (Daniels et al., 2012). The combi-
nation of active targeting transferrin, with the passive
accumulation of liposomes in tumours due to the en-
hanced permeability and retention effect (Maeda,
1992), should provide tumour-selective targeting of
the plumbagin-loaded liposomes to the cancer cells
(Zheng et al., 2010; Guo et al., 2015).
The objectives of this study were therefore (1) to
prepare and characterize transferrin-bearing liposomes
entrapping plumbagin, (2) to assess their cellular up-
take, antiproliferative, and apoptosis efﬁcacy on can-
cer cells in vitro, and (3) to evaluate their
therapeutic efﬁcacy in vivo, following intravenous ad-
ministration to mice bearing tumours.
Materials and Methods
Cell lines and reagents
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone),
human holo-transferrin (Tf), hydrogenated phosphati-
dylcholine, cholesterol, and all other chemicals that
are not speciﬁcally mentioned below were purchased
from Sigma Aldrich (Poole, UK). 1,2-Distearoyl-sn-
glycero-3-phosphoethanolamine-N-(carbonyl-
methoxypolyethyleneglycol 2000), sodium salt (DSPE-
PEG) came from NOF Corporation (Tokyo, Japan).
Cholesterol-PEG5000-maleimide was obtained from
Nanocs (New York, NY).
A431 human epidermoid carcinoma and T98G glio-
blastoma were purchased from the European Collection
of Cell Cultures (Salisbury, UK), while Bioware® B16-
F10-luc-G5 mouse melanoma that expresses the ﬁreﬂy
luciferase was obtained from Caliper Life Sciences
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(Hopkinton, MA). Dulbecco’s modiﬁed Eagle medium
and Roswell Park Memorial Institute (RPMI) 1640 cell
culture media, foetal bovine serum, L-glutamine, and
penicillin–streptomycin were purchased from Life Tech-
nologies (Paisley, UK). Passive lysis buffer was obtained
from Promega (Southampton, UK). Vectashield® mount-
ing medium containing 40,6-diamidino-2-phenylindole
(DAPI) was obtained from Vector Laboratories (Peter-
borough, UK). BD Pharmingen® ﬂuorescein isothiocya-
nate (FITC) Annexin V Apoptosis Detection Kit I was
purchased from BD Biosciences (Franklin Lakes, NJ).
Preparation and characterization of
transferrin-bearing liposomes entrapping
plumbagin
To prepare control liposomes entrapping plumbagin,
a mixture of hydrogenated phosphatidylcholine
(19.2 mg), DSPE-PEG (6.4 mg), cholesterol (5.3 mg),
and cholesterol-PEG-maleimide (1.1 mg) (molar ratios:
60:6:34:0.5) in 3.96 mL PBS (pH 7.4) was shaken at
70°C for 1 h. Plumbagin solution (40 μL, 4 mg, mea-
sured from a stock solution of 100 mg/mL prepared in
dimethylsulfoxide) was then added to the mixture,
followed by probe sonication using Sonics Vibracell®
VCX 500 (Sonics®, Newtown, CT) for 5 × 2 min.
Transferrin was then thiolated to be able to
react with the thiol-reactive maleimide group of
cholesterol-PEG-maleimide (Fig. 1). To do so, 10 mg of
transferrin were dissolved in 1 mL of 50-mM sodium
phosphate and 150-mM sodium chloride buffer (pH 8)
and reacted with 10-fold molar excess of 2-
iminothiolane (Traut’s reagent, 85 μL, 2 mg/mL in dis-
tilled water) at 25°C for 1 h. The thiolated transferrin
was then isolated from unreacted Traut’s reagent using
Vivaspin® six centrifuge tubes with a molecular weight
cut-off of 5 000 Daltons (Sartorius Ltd., Epsom, UK), af-
ter centrifugation at 9 500 rpm (10 500 g) for 15 min at
20°C (Hermle® Z323K centrifuge, Wehingen, Germany).
The freshly synthesized thiolated Tf was immediately
conjugated to the control liposomes under continuous
stirring at 25°C for 2 h. Free plumbagin and/or
unreacted Tf were removed from both Tf-bearing and
control liposomes using Vivaspin® six centrifuge tubes
with a molecular weight cut-off of 100 000 Daltons (Sar-
torius Ltd., Epsom, UK) by centrifugation at 7 500 rpm
(6 600 g) for 15 min at 20°C.
Liposomes were visualized by transmission electron
microscopy, using a FEI Tecnai TF20 (ThermoFisher Sci-
entiﬁc, Waltham, MA) with a Gatan 794 MultiScan®
camera (Gatan, Pleasanton, CA), as previously de-
scribed (Aldawsari et al., 2011).
The entrapment of plumbagin in the liposomes was
quantiﬁed by spectrophotometry using an Agilent
Varian Cary® 50 UV–Vis spectrophotometer (Agilent
Figure 1. Conjugation of transferrin to the liposomes entrapping plumbagin via thioether linkage.
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Technologies, Santa Clara, CA), following disruption of
the liposomes (10 μL) with isopropanol (990 μL). Absor-
bance of the drug was measured at a λmax of 420 nm.
The grafting of transferrin to the liposomes was
quantiﬁed by Lowry assay, as previously reported
(Dufès et al., 2000).
Size and zeta potential of the liposomes were respec-
tively determined by photon correlation spectroscopy
and laser Doppler electrophoresis using a Zetasizer
Nano-ZS® (Malvern Instruments, Malvern, UK).
Stability of the liposomes
The stability of the liposomes was assessed using three
different batches of liposomes. All samples were placed
in vials protected from light and were kept at 4°C for
4 weeks. The size and zeta potential of the samples
were respectively measured by photon correlation
spectroscopy and laser Doppler electrophoresis at spe-
ciﬁc time points (on Days 0, 7, 14, 21, and 28). The
amount of plumbagin remaining in the liposomes was
quantiﬁed by spectrophotometry compared with the
initially entrapped amount.
Drug release from the liposomes
To conﬁrm that plumbagin could be released from the
liposomes, the release proﬁle of the drug was deter-
mined by dialysis at pH 7.4. Plumbagin formulated as
Tf-bearing, control liposomes, or in solution (500 μg in
phosphate buffer) was placed into a SnakeSkin® dialysis
tube with a molecular weight cut-off of 3 500 Daltons
(ThermoFisher Scientiﬁc) and was dialyzed against
50 mL of phosphate buffer (pH 7.4) at 37°C under stir-
ring; 1-mL sample of the dialysate was withdrawn in
triplicates at speciﬁc time points (30 min, then every
hour for the ﬁrst six hours (1, 2, 3, 4, 5, and 6 h), then
every 2 h for the next 6 h (8, 10, and 12 h), and every
24 h for 3 days) and replaced with an equal volume of
fresh medium. The amount of plumbagin in the samples
was quantiﬁed by spectrophotometry and reported as a
percentage cumulative release.
In vitro biological characterization
Cell culture
B16-F10-luc-G5, A431, and T98G cell lines were grown
in either RPMI-1640 medium (for B16-F10-luc-G5 cells)
or in Dulbecco’s modiﬁed Eagle medium (for A431 and
T98G cells) supplemented with 10% (v/v) foetal bovine
serum, 1% (v/v) L-glutamine, and 0.5% (v/v) penicillin–
streptomycin. Cells were cultured at 37°C in a humid
atmosphere of 5% carbon dioxide.
Cellular uptake
Quantiﬁcation of cellular uptake of plumbagin formu-
lated as Tf-bearing, control liposomes, or free in solu-
tion was carried out by spectrophotometry and ﬂow
cytometry.
Cells were seeded at a density of 2 × 105 cells per
well in 6-well plates and grown at 37°C for 72 h before
being treated with plumbagin (10 μg per well), either
entrapped in transferrin-bearing liposomes, control li-
posomes, or in solution. After 3 h treatment, the cells
were harvested and washed twice with cold phosphate
buffered saline (PBS) (3 mL). Cells were then lysed with
5% Triton-X (1 mL per well) and incubated for another
24 h at 37°C. Cell lysates were then centrifuged at
10 000 rpm (9 300 g) for 15 min using an IEC Micromax®
centrifuge (ThermoFisher Scientiﬁc). The amount of
plumbagin in the surfactant was quantiﬁed by spectro-
photometry (λmax: 420 nm), using a FlexStation 3
®
multi-mode microplate reader (Molecular Devices, Sun-
nyvale, CA).
To further conﬁrm the advantage of using
transferrin-bearing liposomes for improving the cellular
uptake, plumbagin was replaced with coumarin-6 as a
ﬂuorescent lipophilic drug model for quantitative and
qualitative measurement of drug cellular uptake in
B16-F10-luc-G5 cells.
For ﬂow cytometry quantiﬁcation, the cells were
seeded and grown as previously described before being
treated with coumarin-6 (50 ng per well), either
entrapped in transferrin-bearing liposomes, control li-
posomes, or in solution. After 2-h incubation, the cells
were washed twice with cold PBS (3 mL) and harvested
using TrypLE® Express (250 μL). Subsequently, 500 μL
RPMI-1640 medium was added to the cell suspension.
Mean ﬂuorescence intensity (MFI) of coumarin-6 taken
up by the cells was quantiﬁed by ﬂow cytometry using
a FACSCanto® ﬂow cytometry (BD Biosciences), with a
FITC ﬁlter (Excmax = 494 nm/Emmax 520 nm). Ten thou-
sand cells (gated events) were counted for each
sample.
The cellular uptake of coumarin-6 was qualitatively
assessed using confocal microscopy. B16-F10-luc-G5
cells (1 × 105 cells per well) were seeded on coverslips
in 6-well plates and were grown for 24 h at 37°C. They
were treated with coumarin-6 (1 μg per well), either
entrapped in Tf-bearing liposomes, control liposomes,
or in solution. After 2 h, the medium was removed,
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and cells were washed twice with cold PBS (3 mL) be-
fore being ﬁxed with 2 mL formaldehyde solution
(3.7% in PBS) for 10 min at 25°C. They were then
washed twice with PBS (3 mL) and incubated at 25°C
with 3 mL Triton-X100 solution (0.1%) for 5 min, before
a further incubation with 3 mL bovine serum albumin
(1% w/v in PBS) for 30 min at 37°C to reduce the non-
speciﬁc binding.
Cells were then stained with Alexa Fluor® 647 dye
(one unit of dye diluted in 200 μL of PBS), incubated
for 20 min at 25°C, before a ﬁnal wash with 3 mL PBS.
Upon staining of the nuclei with Vectashield® mounting
medium containing DAPI, the cells were examined using
a Leica TCS SP5 confocal microscope (Wetzlar,
Germany). DAPI (staining the cell nuclei) was excited
with the 405 nm laser line (emission bandwidth: 415–
491 nm), while Alexa Fluor® 647 (which stained the cell
cytoplasm) was excited with the 633 nm laser line
(emission bandwidth: 645–710 nm), and coumarin-6
was excited with the 505-nm laser line (emission band-
width: 515–558 nm).
Mechanisms of cellular uptake
The mechanisms involved in the cellular uptake of
coumarin-6 entrapped in Tf-bearing liposomes were in-
vestigated using various uptake inhibitors. B16-F10-luc-
G5 cells were seeded in 6-well plates at a density of
2 × 105 cells per well and incubated for 24 h. Cells were
then preincubated with chlorpromazine (20 μg/mL),
ﬁlipin (4 μg/mL), and colchicine (40 μg/mL) at 37°C.
After 30 min incubation, treatment was removed and
replaced with fresh medium containing 50 ng/mL of
coumarin-6 (either entrapped in Tf-bearing, control li-
posomes, or in solution) and the same concentration
of each inhibitor (except chlorpromazine, added at a
concentration of 5 μg/mL) for a further 2 h incubation
at 37°C. Cells were then washed and processed for ﬂow
cytometry analysis as previously described.
In vitro antiproliferative activity
The antiproliferative activity of plumbagin entrapped
in transferrin-bearing liposomes was assessed using a
standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide assay. B16-F10-luc-G5, A431, and
T98G cells were seeded at a density of 5 000 cells per
well in 96-well plates and grown for 24 h before treat-
ment. They were then treated with plumbagin
entrapped in Tf-bearing liposomes, control liposomes,
or in solution, at ﬁnal drug concentrations ranging from
7.81 × 103 to 10 μg plumbagin/mL). Following 24-h
treatment, the antiproliferative activity of the formu-
lations was evaluated by measurement of the growth
inhibitory concentration for 50% of the cell population
(IC50) in a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) assay (n = 15).
Cell apoptosis assay
The number of apoptotic cells following treatment with
plumbagin entrapped in transferrin-bearing liposomes
was determin
ed using BD Pharmingen® FITC Annexin V apoptosis de-
tection kit (BD Biosciences), as described in the manu-
facturer’s instructions. Cells were seeded in 6-well
plates at a density of 2 × 105 cells per well and grown
for 24 h before being treated with plumbagin (1 μg
per well) entrapped in Tf-bearing liposomes, control li-
posomes, or in solution. After 4 h treatment, the cells
were harvested and centrifuged at 2000 rpm (370 g)
for 5 min using an IEC Micromax® centrifuge
(ThermoFisher Scientiﬁc). Subsequently, the cell pel-
lets were resuspended in 200 μL 1× Annexin V Binding
Buffer (10× of the buffer containing 0.1-M
Hepes/NaOH (pH 7.4), 1.4-M NaCl, and 25-mM CaCl2).
Cell suspension (100 μL) was then transferred to a 5-
mL culture tube, followed by 5 μL of Annexin V-FITC la-
belling reagent and 5 μL of propidium iodide and incu-
bated for 15 min at 20°C protected from light. After
incubation, 400 μL of Annexin V Binding Buffer was
added to each tube before analysis of apoptosis using
a FACSCanto® ﬂow cytometer (BD Biosciences). Ten
thousand cells (gated events) were counted for each
sample. The results were reported as percentages of
speciﬁc cell populations (live cells, cells in early apo-
ptosis, late apoptosis, and necrosis).
In vivo tumouricidal activity
The in vivo experiments were approved by the local
ethics committee (the University of Strathclyde Animal
Welfare and Ethical Review Body), complied with the
ARRIVE guidelines and were carried out in accordance
with the UK Home Ofﬁce regulations (UK Animals (Sci-
entiﬁc Procedures) Act 1986).
B16-F10-luc-G5 cancer cells in exponential growth
were subcutaneously implanted to both ﬂanks of fe-
male immunodeﬁcient BALB/c mice (1 × 106 cells per
ﬂank). When tumours were palpable and reached a di-
ameter of 5 mm, the animals were randomized into
groups of ﬁve. They were treated with plumbagin
entrapped in Tf-bearing liposomes, control liposomes,
or in solution, by intravenous tail vein injection
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(2 mg/kg of body weight per injection) once every
2 days for 10 days. The weight of the animal was mea-
sured daily as a surrogate marker of the toxicity of
the treatments. The tumour volume was determined
by calliper measurements (volume = d3 × π/6). The re-
sults were expressed as relative tumour volume (rel.
Voltx = Voltx/Volt0), and the responses were classiﬁed
analogous to Response Evaluation Criteria in Solid Tu-
mors guidelines (Eisenauer et al., 2009). Progressive
disease was deﬁned as an increase in relative tumour
volume higher than 1.2-fold, stable disease as a rela-
tive volume between 0.7 and 1.2 of starting volume,
partial response as measurable tumour with a volume
reduction of more than 30% (0–0.7), and complete re-
sponse as the absence of any tumour.
The therapeutic efﬁcacy of these treatments was
also assessed by bioluminescence imaging, using an IVIS
Spectrum (Caliper Life Sciences). Mice bearing subcuta-
neous B16F10-luc-G5 tumours were intravenously
injected with treatments as described above. On alter-
nate days (Days 1, 3, 5, 7, and 9), they were intraperi-
toneally injected with the luciferase substrate D-
luciferin (150 mg/kg body weight), then anesthetized
using isoﬂurane inhalation 10 min before imaging. The
light emitted from the bioluminescent tumours was de-
tected for 2 min using Living Image® software
(PerkinElmer, Waltham, MA) and displayed as a
pseudo-colour overlay onto a greyscale image of the an-
imal. Identical illumination settings were used for ac-
quiring all images.
Statistical analysis
Results were expressed as means ± standard error of the
mean. Statistical signiﬁcance was assessed by one-way
analysis of variance and Tukey’s multiple comparison
posttest (Minitab® software, State College, PE). Differ-
ences were considered statistically signiﬁcant for P
values lower than 0.05.
Results
Preparation and characterization of
transferrin-bearing liposomes entrapping
plumbagin
Transferrin-bearing and control unilamellar liposomes
entrapping plumbagin have been successfully prepared
by probe sonication, as conﬁrmed by transmission elec-
tron microscopy imaging (Fig. 2). The percentage of
drug loading within these liposomes was relatively high,
respectively 79.2 ± 0.3% for transferrin-bearing lipo-
somes and 78.4 ± 0.4% for control liposomes. The
amount of transferrin conjugated to the liposomes
was 5.1 ± 0.1 mg (50.7 ± 0.5% of the initial transferrin
added). As expected, the conjugation of transferrin to
the surface of the liposomes resulted in a larger aver-
age size of 113 ± 2 nm (polydispersity: 0.33 ± 0.01) than
that of control liposomes (106 ± 1 nm, polydispersity:
0.32 ± 0.01). It slightly decreased their zeta potential
compared with that observed for control liposomes
(18.4 ± 0.4 mV and 17.2 ± 0.1 mV, respectively, for
transferrin-bearing and control liposomes).
Stability of the liposomes
Transferrin-bearing liposomes were found to be stable
when stored at 4°C for at least 4 weeks (Fig. 3). They
displayed a slight decrease in size within 28 days (from
113 ± 2 nm at Day 0 to 102 ± 2 nm at Day 28), unlike con-
trol liposomes, whose size slightly increased (from
Figure 2. Transmission electron micrograph pictures of Tf-bearing (left) and control (right) unilamellar liposomes entrapping plumbagin
(Bar: 100 nm).
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106 ± 1 nm at Day 0 to 115 ± 2 nm at Day 28). However,
blank liposomes appeared to be less stable and signiﬁ-
cantly increased in size during the experiment (from
115 ± 2 nm at Day 0 to 138 ± 4 nm at Day 28) (Fig. 3A).
The zeta potential of the three formulations
remained stable for 28 days (18.4 ± 0.4 mV at Day 0
to 20.2 ± 0.8 mV at Day 28 for Tf-bearing liposomes,
17.2 ± 0.1 mV at Day 0 to 18.6 ± 0.4 mV at Day 28
for control liposomes, and 17.2 ± 0.2 mV at Day 0 to
19.0 ± 0.2 mV at Day 28 for blank liposomes) (Fig. 3B).
In terms of drug leakage, the percentage of
plumbagin retention in both transferrin-bearing and
control liposomes remained stable, with a slight de-
crease of plumbagin (less than 5%) over 4 weeks (from
79.1 ± 0.4% to 75.0 ± 0.9% for transferrin-bearing lipo-
somes and from 78.5 ± 0.4% to 73.6 ± 0.9% for control
liposomes) (Fig. 3C).
Drug release from the liposomes
Transferrin-bearing and control liposomes showed sim-
ilar sustained release proﬁle of plumbagin at pH 7.4,
while plumbagin in solution diffused through the
dialysis membrane to be completely released within
4 h (Fig. 4). The conjugation of transferrin to the sur-
face of liposomes had a slight impact on the release
proﬁle of plumbagin, with a percentage cumulative
release of 88.3 ± 1.5%, slightly lower than that ob-
served with control liposomes (96.5 ± 1.5% during




Figure 3. Size (A), zeta potential (B), and percentage retention
(C) of plumbagin in Tf-bearing ( , blue) and control liposomes
( , red) (▪, black: blank liposomes) after storage at 4°C for 4 weeks
(n = 3).
Figure 4. In vitro drug release proﬁle of plumbagin formulated as
Tf-bearing liposomes ( , blue), control liposomes ( , red), or as
free drug in solution (▪, black) in phosphate buffer at pH 7.4 over
72 h (n = 3).
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Cellular uptake
The entrapment of plumbagin in transferrin-bearing li-
posomes signiﬁcantly improved plumbagin uptake by
the three tested cell lines in comparison with control li-
posomes (by at least 1.4-fold) and plumbagin solution
(by at least 2-fold) (1.66 ± 0.04 mg, 2.16 ± 0.18 mg,
and 3.02 ± 0.20 mg following treatment with
transferrin-bearing liposomes respectively in B16-F10,
A431, and T98G cells; 0.70 ± 0.17 mg, 0.92 ± 0.07 mg,
and 1.43 ± 0.05 mg following treatment with plumbagin
solution respectively in B16-F10, A431, and T98G cells)
(Fig. 5). The highest intracellular amount of plumbagin
was found in T98G cells incubated with transferrin-
bearing liposomes, which was signiﬁcantly higher than
that observed after treatment with control liposomes
and free plumbagin, respectively, by 1.4-fold and 2.1-
fold.
These results were comparable with the cellular
uptake of liposomes entrapping coumarin-6 as a ﬂuores-
cent lipophilic drug model in B16-F10 cells (Fig. 6A).
The conjugation of transferrin to the liposomes
signiﬁcantly increased coumarin-6 uptake (MFI of
5673 ± 49 a.u.) compared with control liposomes (MFI
of 4779 ± 48 a.u.). However, the highest uptake was ob-
served following treatment with coumarin-6 solution
(MFI of 6567 ± 79 a.u.), which might occur by passive
diffusion.
The cellular uptake of coumarin-6 was also qualita-
tively conﬁrmed by confocal microscopy (Fig. 6B). As
expected, Tf-bearing liposomes led to a higher cellular
uptake of coumarin-6 compared with that observed in
control liposomes. Cells treated with free plumbagin
solution showed plumbagin-derived ﬂuorescence in
the cytoplasm, probably due to the nonspeciﬁc diffu-
sion of the drug. Coumarin-6-derived ﬂuorescence was
disseminated in the cytoplasm following all treatments,
with no visible colocalization within the nucleus after
2-h incubation with the treatments.
Mechanisms of cellular uptake
Chlorpromazine, ﬁlipin, and colchicine were used to in-
hibit clathrin-mediated, caveolae-mediated, and
macropinocytosis-mediated endocytosis, respectively
(Cheng et al., 2014).
Pretreatment of B16-F10 cells with chlorpromazine
signiﬁcantly decreased the cellular uptake of
coumarin-6 entrapped in Tf-bearing liposomes, which
was 16% lower than that observed without pretreatment
and 9.7% lower than that observed with control lipo-
somes (respectively 84.3 ± 1.7% and 94.0 ± 0.4% cellular
uptake following treatment with Tf-bearing and control
liposomes, with the relative cellular uptake without in-
hibitor set at 100%) (Fig. 7). The cellular uptake of
coumarin-6 entrapped in Tf-bearing liposomes was also
partially inhibited by ﬁlipin, unlike control liposomes.
It decreased to 92.5 ± 1.7% compared with that mea-
sured in cells without pretreatment. Colchicine, how-
ever, did not inhibit the cellular uptake of Tf-bearing
and control liposomes, meaning that macropinocytosis-
mediated endocytosis pathway was not involved in the
cellular internalization of these liposomes.
In vitro antiproliferative activity
The entrapment of plumbagin in liposome formulations
signiﬁcantly improved the antiproliferative activity of
plumbagin, compared with the free solution, by at least
1.5-fold (Table 1, Fig. 8). The conjugation of transferrin
to the liposomes further increased plumbagin antipro-
liferative efﬁcacy, by 2.3-fold for B16-F10 cells, 4.3-
fold for A431 cells, and 4.2-fold for T98G cells, com-
pared with that of plumbagin solution following 24-h
treatment. The IC50 could not be determined following
treatment of the cells with blank liposomes.
Plumbagin loaded in transferrin-bearing liposomes
exhibited the highest antiproliferative efﬁcacy against
B16-F10 cells (IC50: 0.22 ± 0.01 μg/mL), followed by
A431 cells (IC50: 0.41 ± 0.01 μg/mL). However,
transferrin-bearing liposomes entrapping plumbagin
only exerted a limited antiproliferative effect in T98G
cells (IC50: 1.47 ± 0.27 μg/mL).
Figure 5. Cellular uptake of plumbagin (10 μg per well) either for-
mulated as Tf-bearing liposomes (dark grey), control liposomes
(grey), or as free drug in solution (white), in B16-F10, A431, and
T98G cell lines (n = 5) (*P < 0.05 vs. Tf-bearing liposomes).
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Cell apoptosis assay
The Tf-bearing liposomes entrapping plumbagin (1 μg/
mL, 5.3 μM) signiﬁcantly led to a higher cellular apo-
ptosis in B16-F10 cells compared with that of control li-
posomes and free plumbagin, with 88.4 ± 0.4% of cells
being apoptotic following treatment with Tf-bearing li-
posomes, compared with 82.0 ± 1.5% apoptotic cells
following treatment with control liposomes. By con-
trast, only 27.5 ± 1.0% of cells were apoptotic when
treated with free plumbagin (Fig. 9).
Figure 6. Cellular uptake of coumarin-6 entrapped in Tf-bearing liposomes, control liposomes, or as solution in B16-F10 cells: (A) Mean
ﬂuorescence intensity of coumarin-6 in the cells (n = 3) and (B) qualitative analysis by confocal microscopy.
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In A431 cells, the apoptosis effect of Tf-bearing lipo-
somes (total apoptosis of 43.3 ± 3.5% cells) was lower
than what observed with B16-F10 cells but was still
1.9-fold higher than that observed following treatment
with control liposomes (total apoptosis of 22.4 ± 3.5%
cells). Free plumbagin only exerted a very limited apo-
ptosis effect on this cell line at the tested conditions
(7.9 ± 0.9% apoptotic cells following treatment with free
plumbagin).
In T98G cells, the apoptotic effect of TF-bearing li-
posomes was further reduced compared with that of
the two other cell lines but was still statistically higher
than that observed following treatment with control li-
posomes and free drug in solution (total apoptosis of
24.9 ± 0.8% cells following treatment with Tf-bearing li-
posomes, 18.5 ± 1.0% cells for control liposomes, and
17.1 ± 1.5% cells for free plumbagin).
In vivo tumouricidal activity
The intravenous injection of plumbagin entrapped in
Tf-bearing liposomes and control liposomes led to a
high variability of response to treatment within the
same group of mice and an overall reduced tumour
growth compared with plumbagin solution treatment
(Fig. 10A). For these two treatments, some tumours
kept regressing, while others started growing.
At Day 6, the mice bearing growing tumours had to
be euthanized due to their tumours reaching the maxi-
mum allowed size. The remaining mice whose tumours
were regressing or had completely disappeared were
kept until the end of the study (Day 10). By contrast,
tumours treated with plumbagin solution or blank lipo-
somes grew steadily at a growth rate close to that ob-
served for untreated tumours.
The therapeutic effect resulting from treatment
with liposomes entrapping plumbagin was also qualita-
tively conﬁrmed by bioluminescence imaging on mice
bearing subcutaneous B16-F10-luc tumours (Fig. 11).
Luciferase expression in the tumours treated with the
Tf-bearing and control formulations decreased from
Day 1 to Day 3 but increased again on Day 5. By con-
trast, all the other treatments led to a steady increase
of luciferase expression in the growing tumours.
No apparent signs of toxicity or animal weight loss
were observed during the experiment, thus showing
the good tolerability of all the treatments by the ani-
mals (Fig. 10B).
On the last day of the experiment, 10% of the tu-
mours treated with Tf-bearing liposomes entrapping
plumbagin completely disappeared, while another 10%
of tumours showed a partial response (Fig. 10C). Fol-
lowing treatment with control liposomes, 20% of the tu-
mours were regressing, and 20% were stable. However,
it should be noted that all the mice treated with this
formulation had to be euthanized at Day 6 due to their
Figure 7. Relative cellular uptake of coumarin-6 entrapped in
Tf-bearing liposomes (dark grey) or control liposomes (light
grey), in the presence of endocytosis inhibitors, in B16-F10 cells
(n = 3).
Table 1. Anti-proliferative efﬁcacy of plumbagin entrapped in transferrin-bearing liposomes, control liposomes, or as free drug in solu-
tion, expressed as IC50 values, in B16-F10, A431, and T98G cells, following 24 h treatment (n = 15).
Cell
lines
IC50 (μg/mL) (mean ± SEM)
Tf-bearing liposomes Control liposomes Plumbagin solution Blank liposomes
B16-F10 0.22 ± 0.01 0.31 ± 0.03 0.51 ± 0.02 n.d.
A431 0.41 ± 0.01 0.63 ± 0.02 1.78 ± 0.19 n.d.
T98G 1.47 ± 0.27 2.04 ± 0.35 6.19 ± 0.19 n.d.
n.d., not determined; SEM, standard error of the mean.
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tumours reaching the maximum allowed size (10 mm),
unlike those of Tf-bearing liposomes. By contrast, all
the tumours treated with plumbagin solution, blank li-
posomes, or left untreated were progressive.
The improved therapeutic efﬁcacy observed follow-
ing treatment with Tf-bearing liposomes entrapping
plumbagin resulted in an extended survival of the mice
by 6 days compared with untreated tumours (Fig. 10D).
Discussion
The therapeutic potential of plumbagin has been lim-
ited so far, due to its poor solubility in water, lack of
stability, and low oral bioavailability, which hampered
its biopharmaceutical applications. Plumbagin also
failed to speciﬁcally reach tumours at a therapeutic
concentration due to its lack of tumour speciﬁcity and
rapid elimination, with a short biological half-life.
To overcome these issues, we hypothesized that
loading plumbagin into a tumour-targeted delivery sys-
tem would enhance the speciﬁc delivery of plumbagin
to cancer cells and increase the therapeutic efﬁcacy
both in vitro and in vivo, while at the same time reduc-
ing the secondary effects to healthy tissues.
Liposomes entrapping plumbagin were successfully
prepared by using probe sonication method, as the
self-assembly of lipids into a bilayer is not a spontane-
ous process and generally requires an input of energy
(Gregoriadis, 2006). Transferrin was conjugated to the
control liposomes using the thiol–maleimide “click” re-
action, which is one of the most widely used thiol-based
bioconjugation techniques for grafting delivery systems
with peptides, proteins, or antibodies, due to its high
selectivity, rapid reaction (without heat or catalyst),
and compatibility with aqueous condition (Stenzel,
2013; Ponte et al., 2016). Our results indicated high
level of transferrin conjugation efﬁciency (50.7 ± 0.5%
of the initial Tf added), which was similar to our previ-
ous conjugation rate of around 50% obtained when
using dimethylsuberimidate as a crosslinking agent
(Dufès et al., 2000) or as reported by Lopalco et al.
(2018) when conjugating transferrin to dopamine-
loaded liposomes using ethyl(dimethylaminopropyl)
carbodiimide coupling reagent.
Plumbagin was highly entrapped in both Tf-bearing
and control liposomes (about 80% entrapment). This
was higher than that previously reported when
entrapping plumbagin in niosomes (about 52% entrap-
ment) (Naresh et al., 1996) or in PEGylated liposomes
made of phosphatidylcholine, cholesterol, and DSPE-
Figure 8. Cytotoxicity of plumbagin entrapped in transferrin-
bearing liposomes (black), control liposomes (dark grey), or free
in solution (light grey), on B16-F10 (top), A431 (middle), and
T98G cells (bottom), following 24-h treatment (control: blank li-
posomes (white)) (n = 15).
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mPEG2000 at a molar ratio of 9:3:0.5 (66% entrapment)
(Kumar et al., 2011).
Tf-bearing and control liposomes loaded with
plumbagin displayed small sizes (less than 120 nm),
which was similar to that previously reported when
entrapping plumbagin in PEGylated liposomes, with a
mean size of 115 ± 7 nm (Kumar et al., 2011), or when
entrapping plumbagin in folic acid-conjugated D-α-
tocopheryl polyethylene glycol 1000 succinate
nanomicelles, with a mean size of 128 ± 1 nm (Pawar
et al., 2016). As the cut-off size for extravasation has
been found to be 400 nm for most tumours (Yuan et al.,
1995), these liposomes have the required sizes to be
taken up by the transferrin receptor-expressing cancer
cells.
Tf-bearing liposomes were bearing negative surface
charges, lower than that of control liposomes, which
is most likely due to the negative charge of thiolated
transferrin (22.1 ± 1.4 mV). Similar reduction of zeta
potential upon transferrin conjugation to delivery sys-
tems was observed in our previous studies (Fu et al.,
2011; Lemarié et al., 2013; Karim et al., 2017), as well
Figure 9. Apoptosis induction of B16-F10, A431, and T98G cells treated with plumbagin (1 μg) entrapped in Tf-bearing liposomes, control
liposomes, or free in solution after 4-h treatment. (A) Flow cytometric plots showing the percentage of speciﬁc cell populations (live,
early apoptosis, late apoptosis, and necrosis). (B) Percentage of total apoptotic cells (n = 3) (*P < 0.05 vs. Tf-bearing liposomes).
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as in previous studies by Kircheis et al. (2001). These
negative surface charges would reduce the risk of hav-
ing electrostatic interactions between the liposomes
and the negatively charged serum proteins and cell
membrane, therefore resulting in a prolonged blood
circulation and decrease of the nonspeciﬁc uptake of li-
posomes by healthy cells. Moreover, vesicles with zeta
potential values of ±10 to 20 mV, which is the case for
the liposomes formulated in this study, are considered
to be relatively stable (Bhattacharjee, 2016).
Tf-bearing and control liposomes were stable when
stored at low temperature, with minimal changes in
size and zeta potential, unlike blank liposomes, whose
size signiﬁcantly increased over time. This may be at-
tributed to the presence of plumbagin in the lipid bi-
layer of the liposomes, thus increasing their rigidity
while maintaining their negative surface charge and
preventing liposome agglomeration. A similar observa-
tion was recently reported by Tsermentseli et al.
(2018) regarding the entrapment of shikoni, another
natural naphthoquinone compound, in PEGylated
liposomes made of DOPC, DSPG, and DSPE-mPEG2K.
The authors reported that the drug-loaded liposomes
also displayed a higher size and zeta potential stability
than that of empty liposomes when stored over 28 days
at 4°C.
Plumbagin liposomes showed a sustained release of
the entrapped drug within 10 h. A decrease in the per-
centage cumulative release of plumbagin (observed
from 4 h for the plumbagin solution and from 10 h for
the targeted and control liposomes) can be explained
by the fact that plumbagin can spontaneously evapo-
rate once released from the liposomes and in solution.
However, the release of plumbagin from the Tf-bearing
Figure 10. (A) Tumour growth studies in a B16-F10 murine model after intravenous administration of transferrin-bearing liposomes
entrapping plumbagin (2 mg/kg of body weight/injection) ( , dark green), control liposomes entrapping plumbagin ( , red), bank lipo-
somes ( , blue), plumbagin solution ( , orange), untreated tumours (▪, black) (n = 10). (B) Variations of the animal body weight throughout
the treatment (colour coding as in A). (C) Overall tumour response to treatments at the end of the study, classiﬁed in accordance with the
Response Evaluation Criteria in Solid Tumors (Eisenauer et al., 2009) (red: progressive response; orange: stable response; yellow: partial
response; and green: complete response). (D) Time to disease progression. The Y axis gives the proportion of surviving animals over time.
Animals were removed from the study once their tumour reached 10-mm diameter (color coding as in A).
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liposomes was faster than expected and not pH-optimal
yet. This formulation should therefore be further opti-
mized to prolong drug release as well as accomplish
pH-triggered drug release only extracellularly in the
mildly acidic tumour tissues and intracellularly in the
more acidic endosomes following cellular internaliza-
tion. The release of plumbagin from transferrin-bearing
liposomes followed a similar trend as previously de-
scribed from plumbagin-loaded liposomes (made of
phosphatidylcholine and cholesterol at a 9:1 molar
Figure 11. Bioluminescence imaging of the tumouricidal activity of plumbagin entrapped in F-bearing liposomes(“Tf-lip.”), control lipo-
somes (“control lip.”), or as solution (“Solution”) in a B16-F10-luc tumour model (Controls: Blank liposomes: “Blank lip.” and untreated
tumours “Untreated”). The scale indicates surface radiance (photons/s/cm2/steradian).
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ratio) with 100% cumulative drug release being ob-
served within 12 h at pH 7.4 (Kumar et al., 2011).
In vitro, cellular uptake studies demonstrated that
the conjugation of transferrin to liposomes signiﬁcantly
increased plumbagin uptake in comparison with control
liposomes and plumbagin solution on the three tested
cell lines. A similar result was obtained when replacing
plumbagin with coumarin-6 as a lipophilic ﬂuorescent
drug model. These results were in agreement with our
previous data that showed that the use of transferrin
as a targeting ligand on Solulan-based vesicles im-
proved the uptake of the drugs tocotrienol and epi-
gallocatechin gallate by at least 1.5-fold for the three
tested cell lines (Fu et al., 2009; Lemarié et al.,
2013). They were also in line with another study that
reported that the cellular uptake of resveratrol in
U87MG human glioblastoma cells was increased follow-
ing treatment with Tf-bearing liposomes compared
with control liposomes (Jhaveri et al., 2018).
The cellular uptake of Tf-bearing liposomes was par-
tially inhibited by chlorpromazine and ﬁlipin, while con-
trol liposomes were partially inhibited only by
chlorpromazine. These results conﬁrm the involvement
of clathrin-mediated endocytosis, which is the main
mechanism of nanomedicine internalization (Alshehri
et al., 2018) and caveolae-mediated endocytosis in the
internalization of Tf-bearing liposomes. The decrease
of the drug uptake by the cells was similar to the 20% de-
crease already reported for Tf/TAT-liposomes containing
doxorubicin in B16 cells, following pretreatment with
chlorpromazine (20 μg/ml for 2 h) (Yuan et al., 2016).
Although clathrin-mediated endocytosis pathway
mainly participated in the uptake of both Tf-bearing
and control liposomes, it should be noted that the con-
jugation of transferrin to the surface of control lipo-
somes also partially changed the main uptake pathway
from clathrin-mediated endocytosis to caveolae-
mediated endocytosis. This could have a signiﬁcant im-
pact on the therapeutic efﬁcacy of plumbagin in Tf-
bearing liposomes, as the caveosome is a neutral pH
endocytic compartment, thus partially avoiding the
eventual degradation of the drug by the acidic internal
pH of the endosomes and lysosomes that may occur in
the clathrin-mediated endocytosis pathway (Xiang
et al., 2012). The use of Tf-bearing liposomes therefore
led to a signiﬁcant increase of plumbagin uptake by
B16-F10 cells overexpressing Tf receptors. Free
plumbagin enters the cells by passive diffusion, while li-
posomes are taken up by endocytosis, a slower but
highly speciﬁc process.
The conjugation of transferrin to liposomes in-
creased the antiproliferative activity of plumbagin in
the three tested cancer cell lines. These results corre-
lated with the improved cellular uptake of the drug fol-
lowing treatment with the targeted liposomes.
Although the highest plumbagin uptake was found in
T98G cells after treatment with plumbagin loaded in
Tf-bearing liposomes, improved antiproliferative activ-
ities were found in B16-F10 and A431 cells, probably be-
cause T98G cells are more resistant to plumbagin than
the two other cell lines. T98G cell line is a glioblas-
toma, known to be one of the most malignant and ag-
gressive forms of brain cancer due to its high
resistance to chemotherapy (Kriel et al., 2018). Glio-
blastomas have recently been reported to be resistant
to the alkylating agent temozolomide (Munoz et al.,
2014) and may also be resistant to the alkylating prop-
erties of plumbagin (Klotz et al., 2014), therefore limit-
ing its therapeutic efﬁcacy on T98G cells. Our results
were in accordance with previously published works.
Duraipandy and colleagues have demonstrated that sil-
ver caged nanoparticles entrapping plumbagin at a con-
centration of 2.5 μM (0.47 μg/mL) were able to reduce
the cell viability of A431 cells by 80%, while plumbagin
solution at the same concentration reduced cell viabil-
ity by only 20% (Duraipandy et al., 2014). In another
work, micelles containing plumbagin were shown to im-
prove its in vitro antiproliferative activity on MCF-7
cells by 2.1-fold compared with the drug solution
(Bothiraja et al., 2013). Another targeted formulation
of plumbagin loaded in aptamer-targeted PLGA-PEG
nanoparticles was reported to enhance the cytotoxicity
of the formulation by two-fold compared with
nontargeted nanoparticles (Pan et al., 2017), in line
with our results. However, the IC50 of their targeted
formulation was 4.78 ± 0.83 μM (0.89 μg/mL), which
was higher than what obtained in our experiments on
A431 and B16-F10 cells.
The entrapment of plumbagin in Tf-bearing lipo-
somes also increased apoptosis in the three tested can-
cer cell lines, unlike drug solution. This result
correlated well with those obtained from the antiprolif-
erative assay, showing that Tf-bearing liposomes exhib-
ited the highest antiproliferative effect on B16-F10
cells followed by A431 and T98G cells. Our results were
in agreement with previous reports which demon-
strated that the treatment with plumbagin entrapped
in silver nanocages led to the apoptosis of A431 cells
(Duraipandy et al., 2014) and HeLa cells (Appadurai &
Rathinasamy, 2015), unlike free plumbagin.
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In vivo, we demonstrated that the intravenous ad-
ministration of plumbagin entrapped in Tf-bearing lipo-
somes led to complete tumour eradication for 10% of
B16-F10 tumours and tumour regression for 10% of
these tumours. To our knowledge, it is the ﬁrst time
that the intravenous administration of plumbagin
entrapped in a tumour-targeted delivery system to
mice bearing tumours was able to lead to tumour re-
gression and even complete tumour suppression in
some cases. Other studies have previously demon-
strated the ability of plumbagin entrapped in various
delivery systems to slow down the growth of tumours,
rather than the tumour regression or suppression ob-
served in some instances in our experiments. The intra-
venous administration of plumbagin loaded in niosomes
(3–6 mg/kg) (Naresh et al., 1996) or in PEGylated lipo-
somes (2 mg/kg) (Kumar et al., 2011) has been reported
to slowdown the growth of sarcoma-180 and B16F1 mel-
anoma model in mice, compared with that observed
with the drug solution. Similar therapeutic effects were
also observed when changing the route of administra-
tion of the delivery systems loaded with plumbagin.
The subcutaneous injection of plumbagin entrapped in
PLGA microspheres (10 mg/kg) to BALB/C mice resulted
in a signiﬁcant decrease in tumour growth volume of
sarcoma-180 tumours compared with free plumbagin
(volume-doubling times respectively of 14.3 ± 1.5 days
and 7.2 ± 0.9 days) (Singh et al., 1996). In another
study, the intramuscular administration of plumbagin
entrapped in chitosan-based microspheres (6 mg/kg)
to C57BL/6J mice increased the animals’ lifespan by
30% compared with free plumbagin (which increased
the lifespan by 20%) (Rayabandla et al., 2010).
The most striking effects of the tumour-targeted li-
posomes were the induction of tumour regression
within 1 day after treatment and the disappearance of
the tumours for some animals of this treatment group
within 10 days of treatment. In addition, these effects
occurred using doses of 2 mg/kg, lower than reported
in most other studies. This therapeutic system was able
to act on subcutaneous implanted tumours after
systemic administration and should therefore have the
potential to target multiple metastatic nodules dissem-
inated throughout the body. This therapeutic effect
was promising, although short-lived, and strongly en-
courages the further improvement of these extremely
safe delivery systems, by using a higher dose, slowing
the release rate of the drug from the liposomes, in-
creasing the frequency of the treatment (from every
2 days to every day), and extending the length of the
treatment, which should hopefully lead to an optimized
therapeutic effect.
Conclusion
In this study, we have demonstrated for the ﬁrst time
that a novel formulation of plumbagin entrapped in a
tumour-targeted delivery system can lead to tumour
regression following intravenous administration.
The loading of plumbagin in transferrin-bearing lipo-
somes signiﬁcantly enhanced plumbagin uptake by can-
cer cells, resulting in an improvement of the
antiproliferative (by up to 4.3-fold) and apoptosis efﬁ-
cacies (by up to 5.5-fold) compared with the drug
solution.
In vivo, the intravenous injection of Tf-bearing lipo-
somes entrapping plumbagin led to tumour suppression
for 10% of B16-F10 tumours and tumour regression for a
further 10% of the tumours. By contrast, all the tumours
treated with plumbagin solution or left untreated were
progressive. The animals did not show any signs of
toxicity.
These studies provide a proof of principle that the
entrapment of plumbagin in a tumour-targeted delivery
system is a highly promising strategy for cancer treat-
ment and should be further investigated to optimize
its anticancer therapeutic efﬁcacy.
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